Early Real-World Physician Experience with an Intracanalicular Dexamethasone Insert.
Cynthia MatossianJohn D StephensMichelle K RheeStephen E SmithParag A MajmudarSubba Rao GollamudiRavi H PatelMaria E RosselsonAditi BauskarAlyssa MontiethFabiana Q SilvaSrilatha VantipalliAndrea GibsonJamie Lynne MetzingerMichael H GoldsteinPublished in: Clinical ophthalmology (Auckland, N.Z.) (2022)
The surveys exploring the early use of DEX suggest that DEX is a clinically effective treatment with a rapid initial learning curve and integrates well into clinical use. Physicians had a very positive early experience with DEX, including comfort with insertion and satisfaction. DEX shows promise as a primary treatment choice of physicians for ocular inflammation and pain following cataract surgery by offering patients a hands-free innovative therapy that delivers a preservative-free steroid to the ocular surface over approximately 30 days.
Keyphrases
- primary care
- end stage renal disease
- emergency department
- cataract surgery
- chronic kidney disease
- chronic pain
- ejection fraction
- cross sectional
- peritoneal dialysis
- pain management
- spinal cord
- machine learning
- stem cells
- neuropathic pain
- big data
- quantum dots
- optical coherence tomography
- patient satisfaction
- chemotherapy induced